Drug Profile
Research programme: tregitopes - EpiVax
Alternative Names: Albumin-tregitope; Epi-13Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator EpiVax
- Class Anti-inflammatories; Immunoglobulin fragments; Peptides
- Mechanism of Action Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Asthma
- No development reported Chronic inflammatory demyelinating polyradiculoneuropathy; Glycogen storage disease type II; Hypersensitivity; Type 1 diabetes mellitus
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Allergy in USA (Parenteral)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral)
- 27 Apr 2021 Preclinical development in Hypersensitivity is ongoing in USA